BCAL Diagnostics Limited (ASX: BDX)
Health Care · Biotechnology · AU
AU$0.06
+3.57% today · +7.4% 1Y
BCAL Diagnostics Limited (ASX: BDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.33M and employs 6 people.
Over the last twelve months the share price has gained 7.4%, trading between 0.05 and 0.16.
Tweenvest scores BCAL Diagnostics Limited across four factors: quality 19/100, value 44/100, growth 0/100. Its strongest factor is value.
BDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.33M
- Revenue (TTM)
- $1.69M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.81
- 52-week high
- AU$0.16
- 52-week low
- AU$0.05
- Avg volume (3M)
- —
- Shares outstanding
- 368.68M
- Employees
- 6
- Next earnings
- —
About BCAL Diagnostics Limited
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
- ISIN
- AU0000160921
- Founded
- 2010
- Listed since
- Jul 21, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.